Pharmacopeia
Midodrine
Core pharmacology
- Class Group
Oral peripheral alpha-1 adrenoceptor agonist prodrug; vasopressor.
- Main Action
Increases peripheral vascular resistance and blood pressure without direct beta-adrenergic inotropy.
- Mechanism of action
Midodrine is converted to desglymidodrine, an alpha-1 adrenergic agonist that contracts arteriolar and venous vascular smooth muscle.
- Indications Uses
Symptomatic orthostatic hypotension in selected patients. ICU use to facilitate liberation from intravenous vasopressors is off-label and is not supported for routine use by the MIDAS randomised trial.
- Absorption
Rapid oral absorption; bioavailability of active desglymidodrine about 93%; prodrug peaks at about 30 minutes and active metabolite peaks around 1–2 hours.
- Metabolism
Deglycination in multiple tissues converts midodrine to active desglymidodrine; additional metabolism occurs partly in the liver.
- Excretion
Active metabolite is eliminated mainly via kidneys, with substantial active tubular secretion; exposure may rise with renal dysfunction.
- Half-life
Midodrine prodrug half-life about 25 minutes; active metabolite desglymidodrine about 3–4 hours.
- Adverse Effects Toxicity
Supine hypertension (major limiting toxicity), bradycardia, piloerection/scalp pruritus and urinary retention.
- Special Points
MIDAS RCT: no reduction in vasopressor discontinuation time; bradycardia was more frequent with midodrine (7.6% vs 0%). Avoid implying proven ICU vasopressor-weaning benefit. Monitor supine blood pressure, heart rate and renal function.
Source references
These October 2026 additions were reconciled against the linked sources. Refer to current local formulary guidance for clinical prescribing.